• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

European Commission Publishes Biosimilars Q&A for Patients


January 23, 2017

The European Commission (EC) has today published a Q&A for patients with information on biosimilar medicines.   The document aims to help "empower patients with reliable information on the use of biosimilar medicines as an alternative therapeutic option", providing "unbiased, scientifically correct and yet easy to understand information", according to a press release from Medicines for Europe.    Medicines for Europe is one of the stakeholders involved in drafting the information for the European Medicines Agency (EMA) and EC. Other stakeholders include the European Patients Forum (EPF), the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), the Standing Committee of European Doctors, European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Association for Bio-industries (EuropaBio).   EC is organizing its third annual multi-stakeholder workshop on biosimilar medicines on May 5, 2017. This year's focus will be on developing a Q&A for healthcare professionals. 

Related Videos